Key aspects defining the development and implementation of a regional genomic surveillance strategy for the Eastern Mediterranean Region.
SARS‐CoV‐2
bioinformatics
genomics
influenza
next‐generation sequencing
whole genome sequencing
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
17
05
2023
revised:
24
08
2023
accepted:
20
09
2023
medline:
23
10
2023
pubmed:
20
10
2023
entrez:
20
10
2023
Statut:
epublish
Résumé
The COVID-19 pandemic highlighted the critical role of pathogen sequencing in making informed public health decisions. Initially, the Eastern Mediterranean Region faced limitations in sequencing capacity. However, with robust WHO and stakeholder support, the situation significantly improved. By 2022, COVID-19 sequencing was underway in 22 out of 23 regional countries, with varying throughput and capacity. Notably, three genomic hubs were established in Oman, UAE, and Morocco, playing a key role in providing expanded genomics training and support across the region. While primarily for COVID-19 surveillance, this sequencing capacity offers an opportunity to integrate genomic surveillance into existing networks. This integration can enable early detection and response to high-threat pathogens with pandemic potential. To advance this, WHO/EMRO collaborated with stakeholders to formulate the Eastern Mediterranean Regional Genomic Surveillance Strategy for Emerging Pathogens of Pandemic Concern. Consultative meetings with regional and international genomic surveillance experts identified strategy focal points, key partners, priority pathogens, and implementation steps. As the strategy awaits member states' ratification in Q4 2023, this manuscript outlines pivotal facets defined by member states and the strategic document's key deliverables and opportunities. These efforts aim to yield a substantial positive impact within the region.
Identifiants
pubmed: 37859974
doi: 10.1111/irv.13205
pii: IRV13205
pmc: PMC10583647
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13205Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2023 World Health Organization; licensed by John Wiley & Sons Ltd. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no financial or personal relationships which may have inappropriately influenced them in the writing of this article. All authors are employed by WHO/EMRO.
Références
BMJ Glob Health. 2022 Jun;7(Suppl 3):
pubmed: 35750341
Lancet Infect Dis. 2021 Sep;21(9):e281-e289
pubmed: 33587898
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Appl Transl Genom. 2016 Jul 01;10:2-9
pubmed: 27668169
Bioinformatics. 2016 Dec 15;32(24):3850-3851
pubmed: 27559158
Bull World Health Organ. 2022 Apr 1;100(4):239-239A
pubmed: 35386562
Bioinformatics. 2016 Jan 1;32(1):142-4
pubmed: 26382197
Emerg Microbes Infect. 2021 Dec;10(1):51-65
pubmed: 33306459
Nat Rev Genet. 2018 Jan;19(1):9-20
pubmed: 29129921
Methods Mol Biol. 2020;2204:13-32
pubmed: 32710311
Brief Bioinform. 2021 Mar 22;22(2):616-630
pubmed: 33279989
Lancet Microbe. 2021 Sep;2(9):e481-e484
pubmed: 34337584
PLoS Genet. 2009 Oct;5(10):e1000612
pubmed: 19855822
Int J Infect Dis. 2021 Feb;103:305-307
pubmed: 33333251
J Infect Public Health. 2020 Mar;13(3):391-401
pubmed: 31522968
N Engl J Med. 2019 Dec 26;381(26):2569-2580
pubmed: 31881145
BMJ Glob Health. 2022 Jul;7(Suppl 4):
pubmed: 35850952
Genomics Proteomics Bioinformatics. 2016 Oct;14(5):265-279
pubmed: 27646134
Nat Microbiol. 2019 Jan;4(1):10-19
pubmed: 30546099
Nat Commun. 2020 Dec 9;11(1):6272
pubmed: 33298935
Curr Issues Mol Biol. 2021 Jul 30;43(2):845-867
pubmed: 34449545